Natera, Inc. (NASDAQ:NTRA) Holdings Reduced by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 24.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 802,534 shares of the medical research company's stock after selling 258,637 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.65% of Natera worth $101,882,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in NTRA. Farallon Capital Management LLC lifted its stake in shares of Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company's stock valued at $483,034,000 after purchasing an additional 532,874 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock valued at $315,194,000 after acquiring an additional 85,236 shares during the period. Duquesne Family Office LLC boosted its stake in shares of Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company's stock worth $213,860,000 after acquiring an additional 45,500 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Natera by 25.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company's stock worth $156,092,000 after acquiring an additional 246,246 shares during the period. Finally, Driehaus Capital Management LLC increased its stake in Natera by 14.6% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,220,768 shares of the medical research company's stock valued at $132,197,000 after purchasing an additional 155,802 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Down 0.1 %

Shares of NTRA stock traded down $0.23 during trading hours on Wednesday, hitting $168.09. 64,248 shares of the company were exchanged, compared to its average volume of 1,343,409. The stock has a market capitalization of $22.19 billion, a price-to-earnings ratio of -95.64 and a beta of 1.53. Natera, Inc. has a one year low of $53.88 and a one year high of $171.95. The business's 50-day simple moving average is $133.05 and its two-hundred day simple moving average is $119.08. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the business posted ($0.95) EPS. Natera's quarterly revenue was up 63.9% compared to the same quarter last year. Sell-side analysts predict that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on NTRA shares. StockNews.com lowered Natera from a "hold" rating to a "sell" rating in a report on Thursday, November 14th. Craig Hallum raised their target price on shares of Natera from $121.00 to $157.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. TD Cowen upped their target price on Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Sanford C. Bernstein increased their price objective on Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Finally, BTIG Research lifted their price target on shares of Natera from $125.00 to $135.00 and gave the stock a "buy" rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.59.

Insiders Place Their Bets

In related news, Director Gail Boxer Marcus sold 9,682 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total value of $1,548,926.36. Following the sale, the director now owns 9,704 shares of the company's stock, valued at approximately $1,552,445.92. This trade represents a 49.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 2,700 shares of the business's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the transaction, the insider now owns 284,741 shares of the company's stock, valued at $36,324,409.37. This represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 46,503 shares of company stock valued at $6,325,804 over the last 90 days. 7.60% of the stock is owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.